Chengdu Niuruite Medical Technology

Chengdu Niuruite Medical Technology, also known as NewRadiant, is a clinical-stage Chinese biotechnology company focused on the development and manufacturing of innovative radiopharmaceuticals. Established in 2016, the company has built a comprehensive platform covering the entire lifecycle of nuclear medicine, from radionuclide production to the development of therapeutic and diagnostic radioligands. Its lead program, Yttrium-90 [90Y] glass microspheres, is in late-stage clinical development for the treatment of primary and metastatic liver cancer. Additionally, the company is advancing a robust pipeline of Lutetium-177 and Actinium-225 labeled therapies targeting prostate cancer and neuroendocrine tumors. NewRadiant operates large-scale GMP-compliant facilities in Chengdu and has secured strategic partnerships to ensure a stable supply of medical isotopes.